Business Wire

FEELM

27.5.2022 13:40:10 CEST | Business Wire | Press release

Share
FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 2022

FEELM, the flagship atomization tech brand belonging to SMOORE, today showcased the world's first ceramic coil disposable pod solution series, FEELM Max at Vaper Expo UK 2022 in Birmingham, UK. By launching the solution and showcasing its cutting-edge ceramic coil heating technology, FEELM is introducing ceramic coil to the emerging category of disposable vape.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005197/en/

As a new category in the ascendant, the disposable vape has been growing in popularity since 2020. The market size of disposable (closed system) vaping product has grown to approximately USD2.125 billion in 2021, accounting for 22.7% of global vaping device market share; and it is expected to increase at a GAGR of over 28% from 2022 to 2026, being the fastest-growing category among all vaping products, according to the estimates of Frost & Suvillian. In 2022, the market size of disposable category is expected to reach USD2.72 billion, making up over 43% of closed system vaping products.

However, almost all the existing disposable vapes are equipped with cotton coil, which produces relatively large aerosol particles, leading to inefficient deposition of inhaled particles in the lungs, hence low nicotine delivery and satisfaction, as well as harshness in throat. Soft cotton coils are unable to form a stable structure, hence a high leakage rate and unpleasant burnt taste. Uneven heating of cotton coils could also cause a weak flavor consistency, so that vaping experience will fade gradually. Moreover, the selling points of most disposable vapes currently focus on large-mouth puff count, or rather, the huge number of puffs that the disposable will provide.

To address the three pain points, FEELM unveils the world's first ceramic coil disposable pod solution, FEELM Max is to disposable vapes what internal combustion engine is to airplanes, automobiles, ships, submarines, and trains. It aims to provide the next generation of disposable vapes with a stronger, more reliable and efficient atomization “engine”. Just like internal combustion engine, which features high thermal efficiency, light weight, compact size and maneuverability, marking the coming of the second industrial revolution; FEELM Max is expected to lead another ceramic coil revolution in the global vaping industry, since the launch of FEELM Air in January 2022.

This revolutionary vaping solution has largely improved e-liquid utilization by virtue of a cotton-free structure and microporous ceramic coil. Therefore, its puff number is increased by 25% with the same e-liquid volume, compared with traditional cotton coil disposable vapes. Besides, it can provide an unprecedented silky-smooth vaping experience, thanks to the ceramic coil, which generates smaller vaporized aerosol particles, thereby minimizing residue in throat. In contrast to cotton coil disposable vapes, the smoothness is improved also by 30%. This innovation also boasts extraordinary flavor consistency of over 95%, since ceramic coil can guarantee constant vapor production, so as to bring the same strong and great taste till the last puff.

In addition to the three major benefits, FEELM Max also features 46% increased overall harm reduction performance compared with cotton coil vapes, and ultra-low vaping leakage rate of less than 0.03%, empowered by Maze Leakage-proof Technology. The smaller vaporized aerosol particles generated by FEELM ceramic coil tend to deposit more in the lung, bringing greater and faster satisfaction. Meanwhile, FEELM's patented Flavor-Lock technology can bring tailored flavor release with terraced temperature zones.

In early 2022, FEELM Max has been adopted by a specialist vape retailer in the UK. In partnership with FEELM, this retailer has introduced an ultra-slim disposable product equipped with FEELM ceramic coil. Built to be lightweight and compact, this product is designed specifically for smoking cessation. In April, the two partners participated in VApril 2022, the world’s largest vaping awareness campaign to give away disposable vapes to adult smokers seeking to switch in London and Manchester.

At Vaper Expo UK 2022, FEELM has also showcased other industry-leading, pioneering disposable vaping solutions, for example, eco-friendly non-nicotine disposable e-cigarette and anti-dust mouthpiece hygienic e-cigarette. These two have been awarded Red Dot Awards for Product Design 2022 for their green product concepts and avant-garde design. Unlike traditional disposable e-cigarettes made of plastic, the external structure of eco-friendly non-nicotine disposable e-cigarette is composed of recyclable and reusable paper and aluminum foil while anti-dust mouthpiece hygienic e-cigarette features a twist nozzle to prevent the contact of mouthpiece with something unclean, with the product concept originated from lipsticks.

Another award-winning solution displayed at the event is FEELM Air, the world’s thinnest ceramic coil vape pod solution. In collaboration with its global clients, FEELM has demonstrated a series of vaping products of regional leading brands that adopt FEELM Air solution. Moreover, it will announce the 2022 timeline of commercial launch of FEELM Air on a global scale afterwards.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye